Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer.

<table>
<thead>
<tr>
<th>Journal Title</th>
<th>Cancer science</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>107</td>
</tr>
<tr>
<td>Number</td>
<td>4</td>
</tr>
<tr>
<td>Page Range</td>
<td>514-520</td>
</tr>
<tr>
<td>Year</td>
<td>2016-04</td>
</tr>
</tbody>
</table>

(C) 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

doi: 10.1111/cas.12888
Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer

**Ryoichi Miyamoto, Tatsuya Oda, Shinji Hashimoto, Tomohiro Kurokawa, Yuki Inagaki, Osamu Shimomura, Yusuke Ohara, Keichi Yamada, Yoshimasa Akashi, Tsuyoshi Enomoto, Mikio Kishimoto, Hitoshi Yanagihara, Eiji Kita and Nobuhiro Ohkohchi**

Department of Surgery, Clinical Sciences, Faculty of Medicine, University of Tsukuba, Tsukuba; Institute of Applied Physics, University of Tsukuba, Tsukuba, Japan

Key words: Cetuximab, drug delivery, mild hyperthermia, monoclonal antibody, pancreatic cancer

Correspondence

Tatsuya Oda, Department of Surgery, Clinical Sciences, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.

Tel: +81-298-53-3221; Fax: +81-298-53-3222; E-mail: tatoda@md.tsukuba.ac.jp

Funding Information

This study was supported in part by Grant-in-Aid for Scientific Research (KAKENHI, 20828053 and 23300185) from The Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Received September 11, 2015; Revised January 6, 2016; Accepted January 11, 2016

Cancer Sci 107 (2016) 514–520
doi: 10.1111/cas.12888

Pancreatic cancer is still refractory to treatment, with a 5-year survival rate of 5–7% (1,2). This limited treatment efficacy may be attributable to histological features, such as hypovascularity, (3) and the production of abundant interstitial stroma that surrounds the cancer cells, which is referred to as a desmoplastic reaction. (4) As a result, few chemotherapeutic drugs enter the cancer nodule. Moreover, only a very small proportion of the drug actually reaches the cancer cells because the subsequent diffusion is hampered by the thick interstitial stroma.

Heat has been used to eradicate cancers since the time of Hippocrates (460–370 BC). A subcategory of hyperthermia, referred to as mild hyperthermia, has been in use since the 1970s. Mild hyperthermia involves using a temperature of 41–43°C to improve the effect of co-administered anticancer drugs and radiation. (5) The reasoning behind this approach is that the application of mild heat increases blood flow and the permeability of tumor blood vessels, thereby increasing drug accumulation in the target tissue. (6,7) In fact, applying mild hyperthermia in vivo has been reported to increase blood flow within tumor tissues by up to three-fold and the antitumor effects of drugs by up to 3.6-fold. (8)

Cetuximab, an epidermal growth factor receptor (EGFR)-targeted antibody, is a promising candidate for clinical applications in pancreatic cancer patients because EGFR is highly expressed in pancreatic cancer cells at frequencies of 60–90%. (9) However, treating pancreatic cancer patients with a combination of gemcitabine and cetuximab did not improve patient prognosis compared with treatment with gemcitabine alone. Median survival time (MST) of 5.9–6.3 months, (10) most likely because cetuximab was not adequately delivered to the pancreatic cancer cells following simple i.v. administration.

We therefore reviewed the potential for combining mAb drug treatment with mild hyperthermia to deliver effective amounts of cetuximab to matrix-rich pancreatic cancer. Reports from as early as the 1990s showed enhanced accumulation and an improved antitumor effect when radioimmunochemistry was used in combination with mild hyperthermia, although the booster effect still did not yield satisfactory outcomes. (11,12)
The goal of this study was to determine whether mild hyperthermia could provide a better effect for cetuximab therapy. Using a mouse model of s.c. pancreatic cancer, we provide preclinical evidence that mild hyperthermia enhances cetuximab accumulation and reduces tumor size.

Materials and Methods

Four in vivo pancreatic cancer models with different amounts of stroma. We used three pancreatic cancer cell line-based xenograft models. The human pancreatic cancer cell lines MIAPaCa-2 (CRL-1420), BxPC-3 (CRL-1687), and Capan-1 (HTB-79) were purchased from ATCC (Manassas, VA, USA). The amounts of induced stroma are different between these cell lines: the stroma is abundant in Capan-1 (++), modest in BxPC-3 (+), and very scarce in MIAPaCa-2 (±). To test a more stroma-rich model, we also used a patient-derived tumor fragment transplantation model (Ope-xeno, ++).

The primary generation of Ope-xeno models was established by inoculating 2 \( \times \) 2 \( \times \) 2-mm pieces of surgically resected tissue fragments from human pancreatic cancer patients into the backs of mice with 100 \( \mu \)L Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). The use of the Ope-xeno model was approved by the Ethics Committee of Tsukuba University Hospital (Tsu- kuba, Japan). When the implanted pieces generated tumors of 1 cm in diameter, they were harvested and cut into 2 \( \times \) 2 \( \times \) 2-mm pieces and transplanted into other mice. When these second generation tumors grew, they were minced into 2 \( \times \) 2 \( \times \) 2-mm pieces and preserved in a freezer after soaking in cell cryopreservation medium (Cell Banker 1; Juji Field, Tokyo, Japan). The Ope-xeno model in this study was designated the third generation. When the tumors reached 70 mm\(^3\), they were removed and placed in a water bath for 30 min at different temperatures: 25°C, control temperature; 37°C, intra-abdominal organ level; and 41°C, mild hyperthermia (\( n = 4 \), each treatment group). The cetuximab plus heat treatment was given once every 3 days for a total of 10 applications (Fig. 2). The control group received a normal saline injection plus heat (\( n = 4 \)). The size of each xenograft was determined by measuring the tumor diameter and calculating the tumor volume (\( V \)) using the following formula: \( V = \pi ab^2/6 \) where \( a \) is the maximum diameter and \( b \) is the minimum diameter.

Study 2: quantification of in vivo accumulation of cetuximab in cancer cells and effect of hyperthermia. To objectively determine the amount of hyperthermia-enhanced cetuximab accumulation in vivo in a single cancer cell, we used an immunofluorescence technique using anti-human IgG antibodies that recognized the Fc portion of cetuximab, which were visualized using a fluorescence dye. The mice in all four groups were treated with cetuximab + different temperatures (25, 37, or 41°C, \( n = 4 \) each; i.e., four groups \( \times \) three temperatures) using the same protocol described in Study 1 but for one total session. At 24 h after the treatment, the mice were killed by cervical dislocation, the tumors were excised, and cetuximab accumulation was measured (Fig. 2). The excised tumors were fixed in formalin and sectioned into 2-μm slices.
and biotin was blocked using a biotin-blocking system (Dako Japan, Tokyo, Japan). The sections were then incubated with an HRP-conjugated polyclonal rabbit anti-human IgG antibody (Dako, Glostrup, Denmark) at a 1:100 dilution for 24 h at 4°C, followed by incubation with a biotin-conjugated tyramide signal amplification system (PerkinElmer, Waltham, MA, USA) at a 1:50 dilution for 10 min at room temperature. The tissues were then treated with streptavidin-conjugated Alexa Fluor 488 dye (Alexa 488) (Life Technologies, Grand Island, NY, USA) at a 1:50 dilution for 10 min at room temperature. The tissues followed by counterstaining with DAPI (Life Technologies).

The single cell fluorescence intensity was quantified using a digital microscope (BZ-9000; Keyence, Osaka Japan). A total of 200 × 500 μm², was selected for each section at 200 × magnification, and the total Alexa 488 intensity was divided by the number of cancer cell nuclei (Fig. 3). When selecting the 10 sites, the stromal regions were excluded by manually selecting areas of cancer cells. The cetuximab accumulation per cancer cell in a section was defined as the median value of the 10 sites. The mean value for four mice was recorded.

Statistical analyses. All of the statistical analyses were carried out using ssrs-n for Windows (IBM, Armonk, NY, USA), and the data are presented as the mean ± SD. The F-test was used to account for population variance, and Student’s t-test and the Tukey–Kramer test were used to compare two groups and multiple groups, respectively. P-values <0.05 were considered to be statistically significant. The error bars in the figures represent the SD.

Results

Study 1: tumor growth inhibition by cetuximab and booster effect provided by hyperthermia. In the MIAPaCa-2 Cell-xeno model, cetuximab showed effective antitumor activity at 25°C (Fig. 4a) (●, 123 ± 30 mm³) compared with the Ns + 25°C group (○, 1462 ± 790 mm³). There was no apparent increase in the antitumor effect of cetuximab at 37°C (Fig. 4a) (▲, 109 ± 36 mm³; P = 0.25) or 41°C (■, 151 ± 10 mm³; P = 0.31) at day 50. Hyperthermia alone was not effective, as the average tumor sizes at 37°C (△, 1612 ± 364 mm³) and 41°C (□, 1657 ± 1218 mm³) did not differ from those of the 25°C group (P = 0.33, 0.41) (Fig. 4a). Similar negative effects of heat were confirmed in the other three models.

In the BxPC-3 Cell-xeno model, an intermediate antitumor effect of cetuximab was observed at 25°C (Fig. 4b) (●, 470 ± 244 mm³) compared with the Ns + 25°C group (○, 1059 ± 1076 mm³). This effect was enhanced by combining cetuximab treatment with hyperthermia, as demonstrated at 37°C (▲, 189 ± 228 mm³) and 41°C (■, 121 ± 310 mm³) at day 40 (all P < 0.05).

In the Capan-1 Cell-xeno model, no antitumor effect of cetuximab was observed at 25°C (Fig. 4c) (●, 1070 ± 20 mm³) compared with the Ns + 25°C group (○, 1059 ± 394 mm³). Hyperthermia enhanced the antitumor effect of cetuximab, as significant suppression of tumor growth was observed at 37°C (▲, 789 ± 36 mm³) and 41°C (■, 421 ± 14 mm³) compared with the 25°C group at day 40 (all P < 0.05). Furthermore, 41°C treatment further enhanced the cetuximab antitumor effect compared with 37°C treatment at day 40 (P < 0.05).

In the Ope-xeno model, no antitumor effect of cetuximab was observed at 25°C (●, 778 ± 38 mm³) compared with the Ns + 25°C group (○, 774 ± 82 mm³). Hyperthermia only enhanced the antitumor effect of cetuximab at 41°C (■, 565 ± 120 mm³) at day 70 (P < 0.05) (Fig. 4d).

Study 2: quantification of accumulated cetuximab in a cancer cell and the effect of hyperthermia. The cetuximab accumulation in MIAPaCa-2 cancer cells was sufficiently intense at 25°C (Fig. 5a-i) and did not increase at 37°C or 41°C (Fig. 5a-ii,a-iii). The intensity value at 25°C (1632 ± 960; Fig. 5a-iv, white column) was not increased at 37°C (1921 ± 848, gray column) or 41°C (1949 ± 690, black column) (P = 0.34 and 0.23, respectively).

Fig. 3. (a) Alexa 488 immunofluorescence staining in the BxPC-3 Cell-xeno pancreatic cancer xenograft mouse model. Only the target regions of the cancer cell aggregates were counted (indicated by outlining with a dashed line). (b) Manually selected cancer cell areas with an island-shaped morphology (left), DAPI nuclear staining (middle), and cell counting by digital microscopy (right) in selected cancer cell areas. The sum of the Alexa 488 fluorescence intensity in cancer cells was divided by the number of cancer cells to indirectly quantify cetuximab accumulation per cancer cell.

Fig. 2. In vivo hyperthermia model. Study 1, antitumor effects were determined by measuring tumor volume over time. Study 2, cetuximab accumulation in tumor cells was quantified by immunofluorescence.
The accumulation in BxPC-3 cancer cells was moderate at 25°C (Fig. 5b-i) and increased at 37 and 41°C (Fig. 5b-ii, b-iii). The intensity value at 25°C (1063 ± 1260; Fig. 5b-iv, white column) was increased at 37°C (2980 ± 1438, gray column) and 41°C (3015 ± 816, black column) (all \( P < 0.05 \)).

The accumulation in Capan-1 and Ope-xeno cancer cells was very low at 25°C (Fig. 5c-i, d-i) and increased at 37 and 41°C (Fig. 5c-ii, c-iii, d-ii, d-iii). The intensity value at 25°C (760 ± 756, 461 ± 536; Fig. 5c-iv, d-iv, white column) were increased at 37°C (1881 ± 870, 1469 ± 472, gray column) and 41°C (3615 ± 634, 1922 ± 1740, black column) (all \( P < 0.05 \)). Furthermore, in the Capan-1 Cell-xeno model, the intensity value at 41°C was higher than that at 37°C (\( P < 0.05 \)).

Discussion

The effects of mild hyperthermia on antibody therapy were determined in the 1990s for radioimmunotherapy using stroma-poor colon cancer mouse models.\(^{11,12}\) Although the effectiveness of radioimmunotherapy alone has been insufficient, research in this field advanced very little in the subsequent 20 years. By combining mild hyperthermia with cetuximab treatment, we showed drug accumulation in tumors and potent antitumor effects in an in vivo model of stroma-rich pancreatic cancer.

Optimal cetuximab effects were obtained in the stroma-poor MIAPaCa-2 Cell-xeno model, which showed complete remission without the addition of heat treatment (Fig. 4a). This effect may be attributed to sufficient in vivo accumulation of cetuximab in the cancer cells, as demonstrated by the fluorescence intensity value of 1632/cell (Fig. 5a). Because cetuximab treatment without heat (i.e., at 25°C) was sufficient in the MIAPaCa-2 Cell-xeno model, we confirmed that there was no need for the additive effect of mild hyperthermia.

Stroma is viewed as a hindrance to drug delivery.\(^{4,20}\) In fact, cancer cells are separated from the nearest blood vessels by prominent stromal fibers, and the distances between cancer cells and blood vessels are significantly longer in human pancreatic cancer (47.4 ± 43.0 \( \mu \)m) and in the Ope-xeno model (35.3 ± 39.0 \( \mu \)m) than in the stroma-poor cell xenograft models (3.9 ± 3.1 \( \mu \)m).\(^{13}\) In addition, the vessel density of stroma-rich tumors is lower than that of stroma-poor tumors.\(^{13}\) In terms of the relationship between tumor stroma and hyperthermia, we assumed that stroma-rich cancer would be a better candidate for the booster effect of hyperthermia.

First, we assumed that applying hyperthermia would affect physiological phenomena in the tumor stroma, which includes fibroblasts and endothelial cells. In fact, a previous in vitro study showed that the colony formation of fibroblasts and endothelial cells, which play fundamental roles in tumor stroma, was maximally reduced to 17% and 5%, respectively, in response to hyperthermia.\(^{21}\) Furthermore, previous in vivo studies reported that treating tumors with hyperthermia improved tumor vessel function and increased the pore size of tumor vessels, thus...
increasing anticancer drug extravasation. These findings indicated that hyperthermia could improve drug delivery by reducing the stromal barrier or increasing anticancer drug extravasation.

Second, we assumed that hyperthermia would improve drug delivery by increasing tumor blood flow. Stroma-rich tumors are largely hypovascular; therefore, there is less blood supply per unit of tumor weight than in stroma-poor and hypervascular tumors. We assumed that the blood flow increase after heating compared with before heating would be more pronounced in stroma-rich cancer. The number of vessels, the resultant hypoxia, and the low pH of the intratumor environment are recognized hallmarks of stroma-rich tumors that evoke resistance to anticancer drugs and radiation. After application of mild hyperthermia, the oxygen content and pH of this stroma-rich tumor environment increase, rendering the tumor more susceptible to anticancer drugs and radiation.

The abundance of the tumor stroma is closely related to the effect of cetuximab plus mild hyperthermia treatment. The general explanation for this phenomenon is that tumors with more abundant stroma accumulate less cetuximab, and thus, tumor growth is not inhibited under normal conditions (i.e., at 25°C). In fact, a moderate antitumor effect was observed in the BxPC-3 Cell-xeno model at 25°C; however, this effect was weaker than that observed in the stroma-poor MIA-PaCa-2 Cell-xeno model (Fig. 4b). In the stroma-rich Capan-1 Cell-xeno and Ope-xeno models, we observed no effect at 25°C. With the application of mild heat (37°C), the antitumor effects increased in the BxPC-3 Cell-xeno model and were sig-

![Fig. 5. Cetuximab accumulation in cancer cells in four in vivo pancreatic cancer xenograft mouse models with different stroma amounts. (a) MIAPaCa-2 Cell-xeno model. The intensity values in the cetuximab + 25°C group (iv, white column) did not increase further with treatment at 37°C (gray column) or 41°C (black column). (b) BxPC-3 Cell-xeno model. The intensity values were significantly increased in the 37°C (iv, gray column) and 41°C (black column) groups compared with the cetuximab (Cmab + 25°C group (white column). *P < 0.05. (c) Capan-1 Cell-xeno model. The intensity values in the 37°C (iv, gray column) and 41°C (black column) groups were significantly increased compared with the cetuximab + 25°C group (white column). Furthermore, the Alexa 488 intensity values in the 41°C group (black column) were higher than those in the cetuximab + 37°C group (gray column). *P < 0.05. **P < 0.05. (d) Ope-xeno model. The intensity values were significantly higher in the 37°C (iv, gray column) and 41°C (black column) groups compared with the cetuximab + 25°C group (white column). *P < 0.05.](www.wileyonlinelibrary.com/journal/cas)
nificantly increased in the Capan-1 model (Fig. 4b,c). Moreover, when the temperature was increased to 41°C, the tumors in the BxPC-3 Cell-xeno model were completely eradicated, the effectiveness of cetuximab in the Capan-1 model increased, and we detected an effect in the stroma-rich Ope-xeno model (Fig. 4b-d). Of note, the additive effect of mild hyperthermia appeared to be more significant in stroma-rich cancers, such as the Capan-1 Cell-xeno model.

The antitumor booster effect of mild hyperthermia may be due to increased cetuximab accumulation, as measured by fluorescence intensity values. The baseline accumulation (i.e., at 25°C without heat treatment) of cetuximab was inversely proportional to the amount of stroma present (Fig. 5a–iv–d–iv, white columns), and the values detected in the moderate to rich stroma models were far below the benchmark value of approximately 1600–2000/cell in the MIAPaCa-2 Cell-xeno model. Applying 37°C heat increased these values by 2.8–, 2.5–, and 3.2-fold in the BxPC-3, Capan-1 Cell-xeno and Ope-xeno models, respectively, that were comparable to the baseline value in the MIAPaCa-2 Cell-xeno model of 1600–2000/cell. Moreover, in the stroma-rich Capan-1 Cell-xeno model, treatment with 41°C heat resulted in an increased booster effect of up to 4.8-fold compared with the baseline value of 760/cell at 25°C. Thus, the question arises as to why applying heat has such a considerable effect. One explanation is that mild hyperthermia increases blood flow in the tumor and enhances tumor vessel permeability, thereby promoting cetuximab delivery to the target tumor and enhancing the antitumor effect. The mechanisms underlying the hyperthermia-induced increase in tumor blood flow and tumor vessel permeability have been previously reported.(7,23–25) In terms of the heating period, Song et al. previously reported that the blood flow in mammary adenocarcinoma R3230 tumors increased approximately 1.5-fold immediately after heating at 40.5°C or 41.58°C for 30–60 min, whereas it increased 2.5-fold 24 h after heating at 41.58°C for 60 min.(7,23–25) Therefore, we think that the hyperpermeability of tumor vasculature is maximally enhanced by mild hyperthermia at 24 h after heating.

Tumor blood vessels dilate in response to mildly elevated temperatures, most likely due to smooth muscle relaxation through stimulation by nitric oxide synthesized by endothelial cells. (23) Subsequently, blood enters the dilated arterioles in the tumor and floods the network of capillary-like tumor blood vessels, increasing the intravascular pressure and flow rate.(7) Furthermore, previous in vivo studies have shown that increased hyperthermia-induced blood flow is caused by vessel dilation and the recruitment of capillaries following stimulation with vasoactive compounds such as bradykinin and/or histamine.(24) Regarding the mechanisms underlying hyperthermia-enhanced tumor vessel permeability, the efficacy of most chemotherapeutics is usually predicated on achieving adequate drug transport across the endothelial layer and into the tumor interstitial stroma. The gaps within the endothelial lining are an indication of the stress induced on the tumor vasculature by mild hyperthermia. In response to thermal stress, the loosening or creation of gaps between endothelial cells in tumor vessels improves stromal delivery.(25)

Another possible explanation for the enhanced anticancer effect of cetuximab combined with mild hyperthermia is an increase in the antigen–antibody interaction between cetuximab and EGFR, which is known to be affected by temperature. In fact, Johnstone et al. assessed the effects of temperature over a range of 1–37°C and reported a 2- to 18-fold increase in the association rate and a 20- to 50-fold increase in the dissociation rate of antibodies to and from murine cell surface antigens, respectively.(26) However, the temperature range used for mild hyperthermia, that is, heating from a baseline of 37–45°C, did not affect the association or dissociation rates of the mAb binding.(27) We now understand that altering the interaction kinetics of mAbs does not play a role in the hyperthermia-induced enhancement of mAb targeting to cancer cells.

Tumors that carry k-ras mutations, such as pancreatic cancer, are not candidates for anti-EGFR antibody drug therapy.(28–30) However, our data indicate that cetuximab is effective in pancreatic cancers with the k-ras mutation, such as the MIAPaCa-2 and Capan-1 cell lines. (30,31) If a sufficient amount of the antibody can be delivered to and accumulate at the target site. Moreover, in vivo and in vitro studies that used EGFR knockdown to suppress the proliferation of a pancreatic cancer cell line carrying the k-ras mutation and a clinical study of anti-EGFR antibody drugs in patients with pancreatic cancer showed no differences in outcome related to k-ras status. (30,32) Although the majority (>90%) of clinical pancreatic cancers are positive for k-ras mutation, cetuximab may be effective if used in combination with mild hyperthermia.

The majority of studies investigating mild hyperthermia have conventionally been carried out in settings comparing 25 and 41°C, likely because mild hyperthermia is primarily used to target body surface cancers such as those of the skin or neck. (5,33) However, if we intend to treat i.p. tumors such as pancreatic cancer, which occur in a 37°C environment, then comparisons between heat treatment at 37 and 41°C are indispensible. Because such studies have largely been lacking, the results of the present study provide valuable data showing that cetuximab accumulation and the resulting antitumor effects are enhanced by treatment at 41°C compared with 37°C, especially in the stroma-rich Capan-1 Cell-xeno and Ope-xeno models. Fortunately, microwave or radiofrequency energy applicators for delivering mild hyperthermia, such as the Thermotron RF-8 (Yamamoto Vinita, Osaka, Japan), can be used clinically to treat advanced i.p. tumors. (6) Consequently, combining cetuximab and mild hyperthermia may be a realistic option to consider for the clinical treatment of pancreatic cancer patients.

**Disclosure Statement**

The authors have no conflict of interest.

References


Hyperthermia boosts cetuximab effect